比较疗效和安全性的骨骼肌松弛剂痉挛状态和肌肉骨骼条件:系统回顾。

文章的细节

引用

复制到剪贴板

周R,彼得森K,希尔芬迪M

比较疗效和安全性的骨骼肌松弛剂痉挛状态和肌肉骨骼条件:系统回顾。

J疼痛症状管理。2004年8月,28 (2):140 - 75。

PubMed ID

15276195 (在PubMed

]

文摘

骨骼肌肉松弛剂的异质群体药物用于治疗两种不同类型的基础条件:痉挛状态从上运动神经元症状从边缘肌肉骨骼和肌肉疼痛或痉挛的条件。虽然广泛用于这些迹象,但似乎差距在我们的理解比较不同骨骼肌肉松弛剂的疗效和安全性。这个系统回顾总结和评估的比较疗效和安全性的证据骨骼肌松弛剂对痉挛状态和肌肉骨骼的条件。随机试验(用于比较疗效和不良事件)和观察性研究(仅为不良事件),包括口服药物分为骨骼肌松弛剂被FDA寻求使用电子数据库,引用列表,和制药公司提交。必威国际app2003年1月进行搜索。每个包含的有效性研究是评估使用数据抽象形式和预定义的标准。整个年级中分配给每个关键问题的证据。总共有101个随机试验包括在本文中。没有随机试验被评为质量好,几乎没有证据表明严格评估不良事件包括试验或观察性研究。有公平的证据表明,巴氯芬、tizanidine和丹曲洛林患者是有效的与安慰剂相比痉挛状态(主要是多发性硬化症)。 There is fair evidence that baclofen and tizanidine are roughly equivalent for efficacy in patients with spasticity, but insufficient evidence to determine the efficacy of dantrolene compared to baclofen or tizanidine. There is fair evidence that although the overall rate of adverse effects between tizanidine and baclofen is similar, tizanidine is associated with more dry mouth and baclofen with more weakness. There is fair evidence that cyclobenzaprine, carisoprodol, orphenadrine, and tizanidine are effective compared to placebo in patients with musculoskeletal conditions (primarily acute back or neck pain). Cyclobenzaprine has been evaluated in the most clinical trials and has consistently been found to be effective. There is very limited or inconsistent data regarding the effectiveness of metaxalone, methocarbamol, chlorzoxazone, baclofen, or dantrolene compared to placebo in patients with musculoskeletal conditions. There is insufficient evidence to determine the relative efficacy or safety of cyclobenzaprine, carisoprodol, orphenadrine, tizanidine, metaxalone, methocarbamol, and chlorzoxazone. Dantrolene, and to a lesser degree chlorzoxazone, have been associated with rare serious hepatotoxicity.

DrugBank数据引用了这篇文章

药物

肌安宁